Medpace’s first quarter was marked by substantial year-over-year revenue growth, but management’s discussion centered on increased project cancellations and a lower book-to-bill ratio. CEO August James Troendle called out cancellations reaching their highest point in over a year, attributing the trend to “random items you would expect: product performance, reprioritization, etc.”, with oncology and cardiovascular areas being most affected. Although win rates and initial award notifications were strong, Troendle acknowledged that gross bookings were at the low end, combining with cancellations to pressure backlog and limit net new business growth.
Is now the time to buy MEDP? Find out in our full research report (it’s free for active Edge members).
Medpace (MEDP) Q1 CY2026 Highlights:
- Revenue: $706.6 million vs analyst estimates of $696.3 million (26.5% year-on-year growth, 1.5% beat)
- EPS (GAAP): $4.28 vs analyst estimates of $3.88 (10.2% beat)
- Adjusted EBITDA: $149.4 million vs analyst estimates of $138.1 million (21.1% margin, 8.2% beat)
- The company reconfirmed its revenue guidance for the full year of $2.81 billion at the midpoint
- EPS (GAAP) guidance for the full year is $17.09 at the midpoint, roughly in line with what analysts were expecting
- EBITDA guidance for the full year is $620 million at the midpoint, in line with analyst expectations
- Operating Margin: 20%, in line with the same quarter last year
- Organic Revenue rose 25.8% year on year (beat)
- Market Capitalization: $11.7 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Medpace’s Q1 Earnings Call
-
Maxwell Andrew Smock (William Blair) pressed CEO August James Troendle on the drivers behind elevated cancellations, who cited product-specific factors and noted the bulk occurred in oncology and cardiovascular studies rather than macro or funding issues.
-
David Howard Windley (Jefferies) questioned the impact of cancellations on revenue guidance and visibility. Troendle and CFO Kevin M. Brady stated that while current modeling supports guidance, future cancellations could have near-term effects on revenue.
-
Ann Kathleen Hynes (Mizuho) asked if biopharma M&A influenced cancellations or future exposure. Troendle replied that recent cancellations were not M&A-driven, but acquisitions typically limit future work with absorbed biotech clients.
-
Jailendra P. Singh (Truist Securities) inquired about RFP (request for proposal) trends and market competitiveness. Troendle emphasized that RFP volume was less important than the quality of opportunities and noted no major change in competitive dynamics, though acknowledged a need to improve win rates.
-
Sean Dodge (BMO Capital Markets) sought details on pipeline expansion and hiring strategy. Troendle declined to share specifics but signaled confidence in future growth by continuing to hire and focusing on boosting win rates.
Catalysts in Upcoming Quarters
As we look forward, the StockStory team will monitor (1) trends in project cancellations, particularly in oncology and cardiovascular, to assess whether rates moderate, (2) evidence of higher gross bookings or improved win rates stemming from business development initiatives, and (3) the pace of pre-backlog conversion into revenue. Management’s ability to maintain operating margins while investing in operational efficiencies and talent will also be a key marker of execution.
Medpace currently trades at $410.12, down from $508.46 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
